IDEAYA Biosciences Ready to Connect with Investors
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading force in precision medicine aimed at oncology, has announced its upcoming participation in significant investor relations events. The company is dedicated to discovering and developing targeted therapies to better address the challenges of cancer treatment.
Upcoming Events and Appearances
First on the schedule is Citi's 2025 Global Healthcare Conference, set for December 2. The conference will kick off at 9:00 AM ET, featuring a fireside chat with Yujiro S. Hata, the company’s President and CEO. This discussion will be moderated by Yigal D. Nochomovitz, Ph.D., who serves as the Director of SMid Cap Biotech Analysis.
Citi's 2025 Global Healthcare Conference Details
During this conference, the audience will gain insights into the strategies and future aspirations of IDEAYA. The fireside chat format promises an engaging dialogue, providing attendees with an opportunity to learn directly from the CEO about the company's vision and operational goals.
Next on the Agenda: Evercore Healthcare Conference
Following the Citi conference, IDEAYA will also participate in the 8th Annual Evercore Healthcare Conference on December 3, commencing at 10:50 AM ET. Once again, CEO Yujiro S. Hata will take the stage, this time in conversation with Jonathan Miller, Managing Director of Biotech and Pharma Equity Research.
Evercore Conference Insights
This event will serve as another vital opportunity for IDEAYA to showcase its initiatives in precision oncology. The engaging discussions are expected to attract significant attention from investors and industry professionals alike.
Webcasts and Access to Events
For those unable to attend, a live audio webcast of the conferences will be accessible on the IDEAYA website under the "Investors/Events" section. There will be an option to replay the webcasts for 30 days following the live presentations, making it easier for interested parties to stay informed about the developments in the company.
About IDEAYA Biosciences
IDEAYA's mission revolves around the integration of advanced principles in small-molecule drug discovery with a focus on structural biology and bioinformatics. The company excels in identifying and validating translational biomarkers, which are crucial for developing customized, potentially revolutionary targeted therapies tailored to the genetic underpinnings of cancer. The innovative pipeline at IDEAYA emphasizes synthetic lethality and antibody-drug conjugates (ADCs), aimed specifically at targeted solid tumor indications. The ultimate goal is to deliver precision oncology therapies that are not only effective but also highly personalized to improve outcomes for cancer patients.
Frequently Asked Questions
What is IDEAYA Biosciences focused on?
IDEAYA is dedicated to the discovery and development of targeted therapeutics for oncology, focusing on personalized cancer treatment.
When is IDEAYA participating in investor conferences?
IDEAYA will attend Citi's 2025 Global Healthcare Conference on December 2 and the Evercore Healthcare Conference on December 3.
Who will represent IDEAYA at these events?
CEO Yujiro S. Hata will represent IDEAYA at both conferences, engaging with investors and analysts to share insights about the company.
Where can I watch the conference webcasts?
The webcasts will be available on the IDEAYA website in the "Investors/Events" section, with replays accessible for 30 days post-event.
What innovative therapies is IDEAYA developing?
IDEAYA focuses on synthetic lethality and antibody-drug conjugates as key areas of development in precision oncology therapies.